Relay Medical Teams Up with HaloHealth Angel Network; Initiating a Strategic and Collaborative Partnership

0
62

Toronto, Ontario–(Newsfile Corp. – August 7, 2020) –   Relay Medical Corp. (CSE: RELA) (OTCQB: RYMDF) (FSE: EIY2) (“Relay” or the “Company“), a developer of MedTech innovation, is pleased to report on a strategic partnership with HaloHealth Angel Network.

HaloHealth1 is Canada’s first angel network for healthcare and their mission is simple- wanting to help Canada’s early stage medical companies succeed and grow by connecting them with domain expertise and capital investment from their physician network. HaloHealth offers live investment pitch events, as well as an online platform to discover potential clinical advisors, novel investment opportunities and several other avenues to connect or collaborate within the HealthTech industry.

“We are excited and enthusiastic at the future prospects of a partnership with Relay Medical. We believe our teamwork will foster fruitful synergies and opportunities for both our organizations, and especially to the MedTech industry which we both strive to serve,” said HaloHealth’s Executive Director, Luke Sheen.

If you would like more information about HaloHealth, please visit their website at: https://www.halohealth.ca/.

The Canadian medical landscape is leading the shift from ‘sick care’ to patient-centered ‘health-care’, and various ventures from start-ups to well-established MedTech firms are choosing Canada2 as a test-bed and home to lead the revolution. Just Ontario produces $2.15 billion2 in MedTech exports yearly, and Ontario spends $665 million on research and development in the life sciences sector alone. Canada’s MedTech industry was valued at $8 billion in 2015 and set to hit $12 billion by 2020.3

1https://www.halohealth.ca/
2https://www.investinontario.com/medtech#big-business
3https://www.emergobyul.com/resources/market-canada

About Relay Medical Corp.

Relay Medical is a MedTech innovation Company headquartered in Toronto, Canada focused on the development of novel technologies in the diagnostics and data science sectors.

Website: www.relaymedical.com

Contact:
W. Clark Kent
President
Relay Medical Corp.
Office. 647-872-9982 ext. 2
TF. 1-844-247-6633 ext. 2
investor.relations@relaymedical.com

Bernhard Langer
EU Investor Relations
Office. +49 (0) 177 774 2314
Email: blanger@relaymedical.com

Forward-looking Information Cautionary Statement

Except for statements of historic fact, this news release contains certain “forward-looking information” within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate” and other similar words, or statements that certain events or conditions “may” or “will” occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the Company’s control. There are no assurances that the commercialization plans for HemoPalm Corp. described in this news release will come into effect on the terms or time frame described herein. The Company undertakes no obligation to update forward-looking information if circumstances or management’s estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company’s filings with Canadian securities regulators, which filings are available at www.sedar.com.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/61277

LEAVE A REPLY

Please enter your comment!
Please enter your name here